FormsNet3 - Blank Form


 

 
Sequence Number:    

 

 
Date Received: __ __ __ __ - __ __- __ __  

 

 
CIBMTR Center Number:    

 

 
CIBMTR Recipient ID:    

 

 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

HCT Type: (check all that apply) 

 

 

gfedcb
Autologous

 

 

gfedcb
Allogeneic, unrelated

 

 

gfedcb
Allogeneic, related

Product type: (check all that apply) 

 

 

gfedcb
Bone marrow

 

 

gfedcb
PBSC

 

 

gfedcb
Single cord blood unit

 

 

gfedcb
Multiple cord blood units

 

 

gfedcb
Other product

 

 
Specify:    

 

 
Is this the report of a second or subsequent transplant for the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 

 
1  Is this recipient a registered participant in the United States Immunodeficiency Network (USIDNET)?

    
 nmlkji

yes  
 nmlkji

no  

 

 
2  USIDNET ID:    

 

 
3  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

 

 
4  Is there a family history of hemophagocytic disorders?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify affected member(s): 

 

 
5  Aunt(s)

    
 nmlkji

yes  
 nmlkji

no  

 

 
6  Uncle(s)

    
 nmlkji

yes  
 nmlkji

no  

 

 
7  Cousin(s)

    
 nmlkji

yes  
 nmlkji

no  

 

 
8  Sibling(s)

    
 nmlkji

yes  
 nmlkji

no  

  Key Fields 

Subsequent Transplant 

  Disease Assessment at Diagnosis Questions: 1 - 22

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 1 / 9



 

 
9  Other family member(s)

    
 nmlkji

yes  
 nmlkji

no  

 

 
10  Specify relationship:    

 

 
11  Is there a family history of consanguinity (inter-familial marriage / descent from common ancestors)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
12  Was genetic testing used to confirm the diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify genetic mutation(s) identified: 

 

 
13  FHL 2 / Perforin deficiency (PRF1)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 

 
14  FHL 3 / MUNC 13-4 (UNC13D)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 

 
15  FHL 4 / Syntaxin 11 (STX11)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 

 
16  FHL 5 / Munc 18-2 (STXBP2)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 

 
17  IL2-inducible T-cell kinase (ITK)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 

 
18  Other mutation

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 

 
19  Specify other mutation:    

 

 
20  Were central nervous system (CNS) abnormalities found on computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scans?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
21  Date scan was performed: __ __ __ __ - __ __- __ __  

 

 
22  Was documentation submitted to the CIBMTR?

    (e.g. CT or MRI scan report)  

 nmlkji
yes  

 nmlkji
no  

 

 
23  Anemia

    (Hgb < 9 g/dL)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
24  Degranulation assay of NK cells

    (as defined by local laboratory)  

 nmlkji
Normal  

 nmlkji
Abnormal  

 nmlkji
Unknown  

 

 
25  Fevers

    (>38.5° C or > 101.3° F for >7 days within 1 week of diagnosis) 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

  Clinical Features and Laboratory Studies at Diagnosis Questions: 23 - 47

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 2 / 9



 

 
26  Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
27  Serum ferritin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
28     ng/mL(µg/L) 

 

 
29  Triglycerides

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
30     

 

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 

 
31  Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
32     

 

 

 nmlkji
g/dL  

 nmlkji
mg/dL  

 nmlkji
µmol/L  

 nmlkji
g/L  

 

 
33  NK cell function

    
 nmlkji

Absent  (≤10% lower limit of normal) 

 nmlkji
Decreased  (11-50% lower limit of normal) 

 nmlkji
Normal  

 nmlkji
Unknown  

 

 
34  Neutropenia (ANC < 1.0 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
35  Soluble interleukin-2 receptor alpha chain (sCD25)

    (as defined by local laboratory)  

 nmlkji
Normal  

 nmlkji
Elevated  

 nmlkji
Unknown  

 

 
36  Splenomegaly (spleen palpable > 3 cm below left costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
37  Thrombocytopenia (platelets < 100 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify the cerebrospinal fluid findings at diagnosis 

 

 
38  Neopterin level

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 

 
39  Protein

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 

 
40  WBC count

    
 nmlkji

Normal  (≤ 5 cells/µL) 

 nmlkji
Elevated  (> 5 cells/µL) 

 nmlkji
Not done  

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 3 / 9



Specify the site(s) where hemophagocytosis was documented at diagnosis: 

 

 
41  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 

 
42  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 

 
43  Liver

    
 nmlkji

yes  
 nmlkji

no  

 

 
44  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 

 
45  Spleen

    
 nmlkji

yes  
 nmlkji

no  

 

 
46  Other site

    
 nmlkji

yes  
 nmlkji

no  

 

 
47  Specify other site:    

 

 
48  Were central nervous system (CNS) abnormalities found on computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scans?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
49  Date scan was performed: __ __ __ __ - __ __- __ __  

 

 
50  Were there any clinical neurologic abnormalities present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify neurologic abnormalities: 

 

 
51  Abnormal gait

    
 nmlkji

yes  
 nmlkji

no  

 

 
52  Cranial nerve palsies

    
 nmlkji

yes  
 nmlkji

no  

 

 
53  Developmental delay

    
 nmlkji

yes  
 nmlkji

no  

 

 
54  Motor weakness

    
 nmlkji

yes  
 nmlkji

no  

 

 
55  Seizures

    
 nmlkji

yes  
 nmlkji

no  

 

 
56  Sensory deficits

    
 nmlkji

yes  
 nmlkji

no  

 

 
57  Other neurologic abnormality

    
 nmlkji

yes  
 nmlkji

no  

 

 
58  Specify other neurologic abnormality:    

  Disease Assessment Between Diagnosis and the Start of the Preparative Regimen (Conditioning) Questions: 48 - 58

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 4 / 9



Specify documented infection(s) associated with HLH: 

 

 
59  Was an infection documented?

    
 nmlkji

yes  
 nmlkji

no  

Specify infection(s): 

 

 
60  Cytomegalovirus (CMV)

    
 nmlkji

yes  
 nmlkji

no  

 

 
61  Specify the test method used for diagnosis of CMV

    (check only one)  

 nmlkji
Antigen  

 nmlkji
Polymerase chain reaction (PCR)  

 nmlkji
Shell vial test  

 

 
62  Epstein-Barr virus (EBV)

    
 nmlkji

yes  
 nmlkji

no  

Specify results used for diagnosis of EBV infection: 

 

 
63  In situ hybridization

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
64  Polymerase chain reaction (PCR)

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
65  Serology

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

Specify titers: 

 

 
66  EBNA

    
 nmlkji

Positive  
 nmlkji

Negative  

 

 
67  Early antigen

    
 nmlkji

Positive  
 nmlkji

Negative  

 

 
68  Viral capsid IgG

    
 nmlkji

Positive  
 nmlkji

Negative  

 

 
69  Viral capsid IgM

    
 nmlkji

Positive  
 nmlkji

Negative  

 

 
70  Was documentation submitted to the CIBMTR?

    
 nmlkji

yes  
 nmlkji

no  

 

 
71  Other infection

    
 nmlkji

yes  
 nmlkji

no  

 

 
72  Specify other infection

      

  History of Infection at Any Time Prior to the Preparative Regimen (Conditioning) Questions: 59 - 74

  Other Infection (1) Questions: 72 - 74 

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 5 / 9



 

 
73  If other organism, specify:    

 

 
74  Site

      

 

 
75  Was therapy given?

    
 nmlkji

yes  
 nmlkji

no  

Line of Therapy 

 

 
76  Specify the purpose of therapy

    
 nmlkji

Induction  

 nmlkji
Maintenance  

 nmlkji
Treatment for disease relapse / reactivation  

 

 
77  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
78  Date started: __ __ __ __ - __ __- __ __  

 

 
79  Alemtuzumab (Campath)

    
 nmlkji

yes  
 nmlkji

no  

 

 
80  Specify total dose given:    mg 

 

 
81  Antithymocyte globulin (ATG)

    
 nmlkji

yes  
 nmlkji

no  

 

 
82  Corticosteroids

    (intrathecal) (e.g., IT-A-Hydrocort) 

 nmlkji
yes  

 nmlkji
no  

 

 
83  Corticosteroids

    (systemic) (e.g., Dexamethasone) 

 nmlkji
yes  

 nmlkji
no  

 

 
84  Cyclosporine (CSA, Neoral, Sandimmune)

    
 nmlkji

yes  
 nmlkji

no  

 

 
85  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 

 
86  Intrathecal methotrexate (IT MTX)

    
 nmlkji

yes  
 nmlkji

no  

 

 
87  IVIG

    
 nmlkji

yes  
 nmlkji

no  

  Pre-HCT Therapy Questions: 75 - 107

  Line of Therapy (1) Questions: 76 - 107 

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 6 / 9



 

 
88  Teniposide (VM26)

    
 nmlkji

yes  
 nmlkji

no  

 

 
89  Other therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
90  Specify other therapy:    

 

 
91  Was this therapy given following the HLH-94 / HLH 2004 protocol of the Histiocyte Society?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify response to therapy: 

 

 
92  Was CNS disease inactive?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
93  Normal or stable CT or MRI of CNS

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
94  Neopterin level

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 

 
95  Protein

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 

 
96  WBC count

    
 nmlkji

Normal  (≤ 5 cells/µL) 

 nmlkji
Elevated  (> 5 cells/µL) 

 nmlkji
Not done  

 

 
97  Was systemic disease inactive?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
98  ANC > 1.0 x 109 /L (without growth factor support)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
99  Hemoglobin ≥9 g/dL without transfusion

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
100  Hepatomegaly resolved (≤3cm below costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
101  Normal fibrinogen

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
102  Normal triglycerides

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
103  Platelets > 100 x 109 /L without transfusion

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 7 / 9



 

 
104  Splenomegaly resolved ( ≤3 cm below costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
105  Were there any signs of disease relapse / reactivation?

    
 nmlkji

yes  
 nmlkji

no  

 

 
106  Specify the date of the relapse / reactivation: __ __ __ __ - __ __- __ __  

 

 
107  Specify the site of the relapse / reactivation

    
 nmlkji

CNS  
 nmlkji

Systemic  
 nmlkji

CNS and systemic  

 

 
108  Anemia

    (Hgb < 9 g/dL)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
109  Degranulation assay of NK cells

    (as defined by local laboratory)  

 nmlkji
Normal  

 nmlkji
Abnormal  

 nmlkji
Unknown  

 

 
110  Fevers

    (>38.5° C or > 101.3° F for > 7 days)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
111  Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
112  Serum ferritin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
113     ng/mL(µg/L) 

 

 
114  Triglycerides

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
115     

 

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 

 
116  Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
117     

 

 

 nmlkji
g/dL  

 nmlkji
mg/dL  

 nmlkji
µmol/L  

 nmlkji
g/L  

 

 
118  NK cell function

    
 nmlkji

Absent  (≤10% lower limit of normal) 

 nmlkji
Decreased  (11-50% lower limit of normal) 

 nmlkji
Normal  

 nmlkji
Unknown  

  Clinical Features and Laboratory Studies Prior to the Preparative Regimen (Conditioning) Questions: 108 - 127

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 8 / 9



 

 
119  Neutropenia (ANC < 1.0 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
120  Soluble interleukin-2 receptor alpha chain (sCD25)

    (as defined by local laboratory)  

 nmlkji
Normal  

 nmlkji
Elevated  

 nmlkji
Unknown  

 

 
121  Splenomegaly (spleen palpable > 3 cm below left costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
122  Thrombocytopenia (platelets < 100 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify the cerebrospinal fluid findings at last assessment prior to the start of the preparative regimen 

 

 
123  Neopterin level

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 

 
124  Protein

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 

 
125  WBC count

    
 nmlkji

Normal  (≤ 5 cells/µL) 

 nmlkji
Elevated  (> 5 cells/µL) 

 nmlkji
Not done  

 

 
126  Were central nervous system (CNS) abnormalities found on computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scans?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
127  Date scan was performed: __ __ __ __ - __ __- __ __  

 

 
First Name:    

 

 
Last Name:    

 

 
E-mail address:    

 

 
Date: __ __ __ __ - __ __- __ __  

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2039 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 9 / 9